Search
Results for “farxiga”
Drug facts and side effects, recalls, research, clinical trials and medical reference, from the FDA, the National Library of Medicine and this site.
Drug lookup
Dapagliflozin (Farxiga)
- Not on the FDA shortage list
- No recalls in the last 3 years
What it is used for
FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
How it comes
Tablets: • 5 mg, yellow, biconvex, round, film-coated tablets with “5” engraved on one side and “1427” engraved on the other side. • 10 mg, yellow, biconvex, diamond-shaped, film-coated tablets with “10” engraved on one side and “1428” engraved on the other side. • Tablets: 5 mg and 10 mg ( 3 )
Full prescribing information (DailyMed) (opens in a new tab) Patient information (MedlinePlus) (opens in a new tab)
From the FDA drug label and openFDA records. For reference, not medical advice.
Most-reported side effects
63,809 reports to the FDA
- Death8,630
- Nausea2,831
- Fatigue2,810
- Diarrhoea2,628
- Dizziness2,567
- Dyspnoea2,372
- Off label use2,287
- Blood glucose increased2,221
- Weight decreased2,210
- Acute kidney injury2,145
From the FDA Adverse Event Reporting System. These are voluntary reports: they do not show that the drug caused the event, or how often it happens.
Research
4,736 articles in PubMed, most relevant first
Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure (opens in a new tab)
Cox ZL, Collins SP, Hernandez GA, et al.
Dapagliflozin: A Review in Type 2 Diabetes (opens in a new tab)
Dhillon S
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease (opens in a new tab)
Chertow GM, Vart P, Jongs N, et al.
Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2 (opens in a new tab)
Wu Q, Yao Q, Hu T, et al.
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (opens in a new tab)
Wheeler DC, Toto RD, Stefánsson BV, et al.
Drugs for type 2 diabetes (opens in a new tab)
Clinical trials
788 studies on ClinicalTrials.gov
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance (opens in a new tab)
Sherihan AboElyazed Mohamed Khalil
HbA1c Variability in Type II Diabetes (opens in a new tab)
Weill Cornell Medical College in Qatar
The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study (opens in a new tab)
University of California, San Francisco
Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients (opens in a new tab)
AstraZeneca
Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting (opens in a new tab)
Pyatigorsk City Clinical Hospital Number 1
Effects of Single Oral Dose Dapagliflozin QT Study (opens in a new tab)
AstraZeneca
Medical reference
StatPearls, for clinicians
Research, trials and reference come from the National Library of Medicine (PubMed, ClinicalTrials.gov, StatPearls on the NCBI Bookshelf, MedlinePlus); drug facts, side-effect reports and recalls from the FDA. For reference, not medical advice.